Mineralys Therapeutics Inc

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mineralys Therapeutics advances in cardio renal disorders amid financial strength

Mineralys Therapeutics is strategically positioned to address aldosterone-driven cardio renal disorders with a strong focus on hypertension and chronic kidney disease.
While the company boasts a robust financial position and progress in clinical trials, challenges such as therapeutic outcomes and regulatory requirements need to be carefully navigated.
Amidst uncertainties and risks, Mineralys Therapeutics has opportunities to expand its product portfolio, explore strategic partnerships, and address unmet medical needs in the cardio renal space.

Mineralys Therapeutics reports positive trial results amidst financial challenges

Mineralys Therapeutics shows promise with positive trial results and a strong cash position, but faces challenges with revised trial timelines and financial losses.
The company's focus on expanding its drug pipeline and governance structure presents opportunities for future growth and market penetration.
Navigating patient enrollment, market potential assessment, and cost management will be crucial for Mineralys to capitalize on its strengths and opportunities.

Mineralys Therapeutics advances hypertension treatment with promising trials and financial insights

Mineralys Therapeutics is making significant progress in developing lorundrostat for hypertension treatment.
Despite challenges in trials and financial pressures, the company remains optimistic and committed to advancing its programs.
Analyst questions and discussions during the earnings call reflect a comprehensive approach to addressing key industry topics.

Mineralys Therapeutics Inc reports Q1 loss, progresses in hypertension trials

Mineralys Therapeutics Inc faces financial challenges with increased expenses but shows strength in clinical trial progress and targeted treatment approaches. Opportunities lie in expanding drug benefits and preventing kidney damage through effective hypertension treatment.

Mineralys Therapeutics progresses key trials amidst financial challenges in Q2

Mineralys Therapeutics is advancing its lead asset lorundrostat for hypertension with key trials progressing as planned.
Financially, the company remains well-capitalized but faces challenges with increased R&D expenses impacting net loss.
Management's confidence in program progress and upcoming milestones signals a positive outlook for the company's future.

Mineralys Therapeutics advances lorundrostat trials amidst financial strength

Mineralys Therapeutics is making notable progress in clinical development, supported by a solid financial position. While facing challenges in trial endpoints and safety concerns, the company has opportunities to capitalize on positive trial outcomes and address investor inquiries effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

NEW YORK CITY, NY / ACCESSWIRE / September 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS.

Bronstein, Gewirtz & Grossman, LLC Encourages Mineralys Therapeutics, Inc.(MLYS) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / September 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mineralys Therapeutics, Inc.(MLYS) And Encourages Investors to Reach Out

LOS ANGELES, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. (“Mineralys” or “the Company”) (NASDAQ: MLYS) for violations of the securities laws.

MLYS Investors Have Opportunity to Join Mineralys Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

NEW YORK CITY, NY / ACCESSWIRE / September 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS). Investors who purchased Mineralys securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MLYS.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mineralys Therapeutics, Inc.(MLYS) And Encourages Stockholders to Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Mineralys Therapeutics Inc May Have Violated Securities Laws And Shareholders Are Invited To Help The Schall Law Firm's Inquiry

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells Fargo Rami Katkhuda - LifeSci Capital Operator Welcome to the Mineralys Therapeutics Second Quarter 2024 Conference Call. At this time all lines are in a listen-only mode.

Mineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call Transcript

Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024 Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Garth Russell – LifeSci Advisors Jon Congleton – Chief Executive Officer Adam Levy – Chief Financial Officer David Rodman – Chief Medical Officer Conference Call Participants Jack Padovano – Stifel Seamus Fernandez – Guggenheim Securities Michael DiFiore – Evercore Rami Katkhuda – LifeSci Capital Rich Law – Goldman Sachs Mohit Bansal – Wells Fargo Operator Good morning, ladies and gentlemen, and welcome to the Mineralys First Quarter 2024 Earnings Conference Call. At this time all lines are in listen-only mode.

Mineralys Therapeutics, Inc. (MLYS) Q1 2024 Earnings Call Transcript

– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 –

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024.

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

Acrivon Therapeutics Inc

Avantis U.S. Small Cap Value ETF

iShares Core S&P Small Cap ETF

iShares Russell 2000 ETF

iShares Russell 2000 Value ETF

NEXTracker Inc

Skyward Specialty Insurance Group Inc

SPDR S&P 500 ETF Trust

Vanguard Small-Cap ETF

Vanguard Russell 2000 ETF

Despite the case for small caps, it is recommended to sell the Russell 2000 and related ETFs due to negative alpha and seasonal factors.

What To Buy After You Sell The Russell 2000

Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript

– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 a nd Launch-HTN trial in 2H 2025 –

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

Mineralys: 2nd Half 2024 Hypertension Data Readout

RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.

Mineralys Therapeutics Announces $120 Million Private Placement Financing

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know

RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer.

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment.

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Mineralys Therapeutics Inc. (NASDAQ:MLYS ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Greg Harrison - Bank of America Jack Padovano - Stifel Seamus Fernandez - Guggenheim Securities Mohit Bansal - Wells Fargo Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions].

Mineralys Therapeutics Inc. (MLYS) Q3 2023 Earnings Call Transcript

– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone –

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference being held in Miami on November 28-30.

Mineralys Therapeutics to Participate in Three Upcoming Conferences

– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 –

News for Mineralys Therapeutics Inc Stock (MLYS)